Published in Oncotarget on July 12, 2016
The α-melanocyte stimulating hormone/peroxisome proliferator activated receptor-γ pathway down-regulates proliferation in melanoma cell lines. J Exp Clin Cancer Res (2017) 0.75
Silver nanoparticles enhance the apoptotic potential of gemcitabine in human ovarian cancer cells: combination therapy for effective cancer treatment. Int J Nanomedicine (2017) 0.75
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science (1997) 24.61
Identification of c-MYC as a target of the APC pathway. Science (1998) 24.25
Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol (2002) 10.95
The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A (1999) 10.75
WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet (2004) 10.38
Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science (1997) 8.99
Wnt signaling: is the party in the nucleus? Genes Dev (2006) 4.10
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature (2015) 3.86
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature (2012) 3.83
Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell (2002) 3.72
Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev (2006) 2.87
Control of neural crest cell fate by the Wnt signalling pathway. Nature (1998) 2.71
Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature (2005) 2.44
Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A (2009) 2.41
Wnt signaling in stem and cancer stem cells. Curr Opin Cell Biol (2013) 2.35
Can we safely target the WNT pathway? Nat Rev Drug Discov (2014) 2.31
Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol (1999) 2.30
The WNT/Beta-catenin pathway in melanoma. Front Biosci (2006) 2.09
Loss of beta-catenin expression associated with disease progression in malignant melanoma. Br J Dermatol (2001) 2.00
Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. J Cell Biol (2002) 2.00
Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev (2007) 1.98
Direct regulation of nacre, a zebrafish MITF homolog required for pigment cell formation, by the Wnt pathway. Genes Dev (2000) 1.87
Nucleo-cytoplasmic distribution of beta-catenin is regulated by retention. J Cell Sci (2006) 1.78
Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev (1999) 1.72
A unique DNA binding domain converts T-cell factors into strong Wnt effectors. Mol Cell Biol (2007) 1.70
Controversies at the cytoplasmic face of the cadherin-based adhesion complex. Curr Opin Cell Biol (1999) 1.63
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer (2013) 1.61
A re-evaluation of the "oncogenic" nature of Wnt/beta-catenin signaling in melanoma and other cancers. Curr Oncol Rep (2010) 1.52
Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res (2005) 1.49
In melanoma, beta-catenin is a suppressor of invasion. Oncogene (2011) 1.40
Microphthalmia-associated transcription factor interacts with LEF-1, a mediator of Wnt signaling. EMBO J (2002) 1.37
Pigmentation PAX-ways: the role of Pax3 in melanogenesis, melanocyte stem cell maintenance, and disease. Pigment Cell Melanoma Res (2008) 1.35
Identification of a promoter-specific transcriptional activation domain at the C terminus of the Wnt effector protein T-cell factor 4. J Biol Chem (2002) 1.35
Wnt signaling in liver cancer. Curr Drug Targets (2008) 1.34
The microphthalmia-associated transcription factor Mitf interacts with beta-catenin to determine target gene expression. Mol Cell Biol (2006) 1.31
A new beta-catenin-dependent activation domain in T cell factor. J Biol Chem (2003) 1.29
β-Catenin signaling increases during melanoma progression and promotes tumor cell survival and chemoresistance. PLoS One (2011) 1.25
Planar cell polarity genes and neural tube closure. Birth Defects Res C Embryo Today (2003) 1.25
Expression of the embryonic stem cell transcription factor SOX2 in human skin: relevance to melanocyte and merkel cell biology. Am J Pathol (2009) 1.22
Relationship of beta-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice. Carcinogenesis (1999) 1.18
Beta-catenin inhibits melanocyte migration but induces melanoma metastasis. Oncogene (2012) 1.18
Wnt signaling and prostate cancer. Curr Drug Targets (2008) 1.17
Upregulation of TCF4 expression as a transcriptional target of beta-catenin/p300 complexes during trans-differentiation of endometrial carcinoma cells. Lab Invest (2005) 1.12
WNTS and WNT receptors as therapeutic tools and targets in human disease processes. Front Biosci (2007) 1.11
Prognostic significance of cadherin-based adhesion molecules in cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev (2008) 1.10
Metastatic potential of human melanoma cells in nude mice--characterisation of phenotype, cytokine secretion and tumour-associated antigens. Br J Cancer (1996) 1.09
A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts. PLoS One (2012) 1.07
GSK3beta inhibition promotes melanogenesis in mouse B16 melanoma cells and normal human melanocytes. Cell Signal (2008) 1.06
Chemical-genetic screen identifies riluzole as an enhancer of Wnt/β-catenin signaling in melanoma. Chem Biol (2010) 1.05
Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching. Pigment Cell Melanoma Res (2011) 1.04
Pharmacological modulation of beta-catenin and its applications in cancer therapy. J Cell Mol Med (2013) 1.03
Wnt/β-catenin signaling is stimulated by α-melanocyte-stimulating hormone in melanoma and melanocyte cells: implication in cell differentiation. Pigment Cell Melanoma Res (2011) 0.96
The Wnts of change: How Wnts regulate phenotype switching in melanoma. Biochim Biophys Acta (2015) 0.95
Activation of Wnt/β-catenin signaling increases apoptosis in melanoma cells treated with trail. PLoS One (2013) 0.95
Differentiation and the tumorigenic and metastatic phenotype of murine melanoma cells. Int J Cancer (1990) 0.94
Overexpression of a set of genes, including WISP-1, common to pulmonary metastases of both mouse D122 Lewis lung carcinoma and B16-F10.9 melanoma cell lines. Br J Cancer (2003) 0.93
Phosphorylation of β-catenin results in lack of β-catenin signaling in melanoma. Int J Oncol (2011) 0.87
The role of VEGF in melanoma progression. J Res Med Sci (2012) 0.85
Phosphorylation of β-catenin at serine 663 regulates its transcriptional activity. Biochem Biophys Res Commun (2012) 0.85
The immunohistochemistry of invasive and proliferative phenotype switching in melanoma: a case report. Melanoma Res (2010) 0.85
Negative-feedback regulation of the Wnt pathway by conductin/axin2 involves insensitivity to upstream signalling. J Cell Sci (2014) 0.85
Molecular basis for the tissue specificity of β-catenin oncogenesis. Oncogene (2012) 0.83
Molecular pathways: epigenetic modulation of Wnt-glycogen synthase kinase-3 signaling to target human cancer stem cells. Clin Cancer Res (2014) 0.83
Association of p53 Arg72Pro polymorphism and beta-catenin accumulation in mycosis fungoides. Br J Dermatol (2006) 0.82
Wnt5a attenuates Wnt/β-catenin signalling in human dermal papilla cells. Exp Dermatol (2013) 0.81
Bovine colostrum promotes growth and migration of the human keratinocyte HaCaT cell line. Growth Factors (2009) 0.80
Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3. PLoS One (2015) 0.79
Preclinical studies of a specific PPARγ modulator in the control of skin inflammation. J Invest Dermatol (2013) 0.85
EGFR/ERBB receptors differentially modulate sebaceous lipogenesis. FEBS Lett (2015) 0.76
Maximizing non-enzymatic methods for harvesting adipose-derived stem from lipoaspirate: technical considerations and clinical implications for regenerative surgery. Sci Rep (2017) 0.75
Vitiligo Skin: Exploring the Dermal Compartment. J Invest Dermatol (2017) 0.75
The activation of PPARγ by 2,4,6-Octatrienoic acid protects human keratinocytes from UVR-induced damages. Sci Rep (2017) 0.75
Angiopoietin-like 4, a protein strongly induced during sebocyte differentiation, regulates sebaceous lipogenesis but is dispensable for sebaceous gland function in vivo. J Dermatol Sci (2014) 0.75